TD Cowen maintains Alamar Biosciences at Buy, raises price target to $36 from $34
TD Cowen reaffirmed its Buy rating for Alamar Biosciences and increased its price target to $36 from $34, suggesting a 19.1% upside from the Nov 3 close of $30.22.
How this was made

The 30-second read
Why it matters
The price‑target increase signals confidence but lacks a concrete catalyst, so any price move may be modest.
Market read
Analyst rating change provides a modest trading signal for ALRM.
What to watch
No new clinical data or regulatory events accompany the upgrade.
Background
Alamar Biosciences is a small‑cap biotech firm; analyst upgrades often move such stocks.
Market effects
May lift sentiment in the biotech small‑cap space.
Limited to U.S. biotech investors.
Minimal global impact.
Counterpoint
The target raise could be premature if upcoming trial data disappoint.
Key entities
- analystTD Cowen
Equity research firm that issued the rating upgrade.
- companyAlamar Biosciences
Biotech company receiving the upgraded target.



